PE20040465A1 - Heteroariloxi-ariloxi-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa - Google Patents

Heteroariloxi-ariloxi-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa

Info

Publication number
PE20040465A1
PE20040465A1 PE2003000399A PE2003000399A PE20040465A1 PE 20040465 A1 PE20040465 A1 PE 20040465A1 PE 2003000399 A PE2003000399 A PE 2003000399A PE 2003000399 A PE2003000399 A PE 2003000399A PE 20040465 A1 PE20040465 A1 PE 20040465A1
Authority
PE
Peru
Prior art keywords
triona
pyrimidine
alkyl
substituted
iloxi
Prior art date
Application number
PE2003000399A
Other languages
English (en)
Inventor
Lilli Ann Wolf-Gouveia
Mark Carl Noe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20040465A1 publication Critical patent/PE20040465A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 ES H, (R2)2n+1-(C)n- O CICLOALQUILO(C3-C7) OPCIONALMENTE SUSTITUIDO CON HALO, ALQUILO(C1-C4), ALQUENILO(C1-C4), R3-, R3-O-, PERFLUOROALCOXI(C1-C4), ENTRE OTROS; n ES DE 1 A 5; R2 ES UN HALO, ALQUENILO(C1-C4), ALQUINILO(C1-C4), R3(C=O)-O-, ENTRE OTROS; X ES -O-, >C=O, -S-, >SO2, >S=O, >NR5, -CH2-, -CH2O-, ENTRE OTROS; A ES ARILO(C6-C10) O HETEROARILO(C1-C10) OPCIONALMENTE SUSTITUIDO CON HALOGENO, CN, OH, ALQUILO(C1-C4), PERFLUOROALQUILO(C1-C4) ENTRE OTROS; Y ES UN ENLACE -O-, -S-, >C=O, >SO2, >S=O, -CH2SO2-, ENTRE OTROS; B ES UN HETEROCICLILO(C1-C10) CON AL MENOS UN NITROGENO EL CUAL SE ENLAZA CON UN C DE G; G ES UN ALQUILO(C1-C6) QUE PUEDE ESTAR SUSTITUIDO CON 1 O 3 SUSTITUYENTES DE HALOGENO, CN, OH, -(C=O)-NH2, ENTRE OTROS, O ES R7-(CR8R9)p; DONDE p ES DE O A 4; R7 ES CICLOALQUILO(C3-C7), ARILO(C6-C10), HETEROARILO(C1-C10), ENTRE OTROS; R8 Y R9 SON H, ALQUILO(C1-C4) O FORMAR UN ANILLO CARBOCICLICO DE 3 A 8 MIEMBROS. SON COMPUESTOS PREFERIDOS: 5-(2-METOXIETIL)-5-[4-(1-PIRIDIN-3-IL-1H-INDAZOL-5-ILOXI)FENOXI]PIRIMIDINA-2,4,6-TRIONA, 5-{4-[1-(4-FLUOROFENIL)-1H-INDAZOL-5-ILOXI]FENOXI}-5-(2-METOXIETIL)PIRIMIDINA-2,4,6-TRIONA, 5-{4-[1-(6-CLOROPIRIDIN-3-IL)-1H-INDAZOL-5-ILOXI]FENOXI}-5-(2-METOXIETIL)PIRIMIDINA-2,4,6-TRIONA. TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS. ESTOS COMPUESTOS SON INHIBIDORES DE METALOPROTEINASAS DE MATRIZ Y SON UTILES EN EL TRATAMIENTO DE INFLAMACION, CANCERES, TRANSTORNOS INMUNOLOGICOS.
PE2003000399A 2002-04-26 2003-04-22 Heteroariloxi-ariloxi-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa PE20040465A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37597402P 2002-04-26 2002-04-26

Publications (1)

Publication Number Publication Date
PE20040465A1 true PE20040465A1 (es) 2004-07-24

Family

ID=29270739

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000399A PE20040465A1 (es) 2002-04-26 2003-04-22 Heteroariloxi-ariloxi-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa

Country Status (15)

Country Link
US (1) US6919332B2 (es)
EP (1) EP1507535A1 (es)
JP (1) JP2005529889A (es)
AR (1) AR039660A1 (es)
AU (1) AU2003223012A1 (es)
BR (1) BR0309556A (es)
CA (1) CA2483500A1 (es)
DO (1) DOP2003000632A (es)
GT (1) GT200300098A (es)
MX (1) MXPA04010550A (es)
PA (1) PA8572101A1 (es)
PE (1) PE20040465A1 (es)
TW (1) TW200406407A (es)
UY (1) UY27775A1 (es)
WO (1) WO2003090751A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE441417T1 (de) 2002-12-20 2009-09-15 Glaxo Group Ltd Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
PL1750862T3 (pl) 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US20080032960A1 (en) 2006-04-04 2008-02-07 Regents Of The University Of California PI3 kinase antagonists
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
NZ613219A (en) * 2008-01-04 2014-11-28 Intellikine Llc Heterocyclic containing entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CN102124009B (zh) 2008-07-08 2014-07-23 因特利凯公司 激酶抑制剂及其使用方法
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA115767C2 (uk) 2011-01-10 2017-12-26 Інфініті Фармасьютікалз, Інк. Способи отримання ізохінолінонів і тверді форми ізохінолінонів
CN106619647A (zh) 2011-02-23 2017-05-10 因特利凯有限责任公司 激酶抑制剂的组合及其用途
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
EP2751112B1 (en) 2011-09-02 2019-10-09 The Regents of The University of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA201690713A1 (ru) 2013-10-04 2016-08-31 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10647692B2 (en) 2015-03-12 2020-05-12 Fmc Corporation Heterocycle-substituted bicyclic azole pesticides
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
BR112018012010A2 (pt) 2015-12-14 2018-12-04 Fmc Corporation composto, composição, método de controle de pragas invertebradas e semente tratada
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20190033526A (ko) 2016-06-24 2019-03-29 인피니티 파마슈티칼스, 인코포레이티드 병용 요법
WO2018213377A1 (en) 2017-05-17 2018-11-22 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN117003754A (zh) * 2022-04-28 2023-11-07 腾讯科技（深圳）有限公司 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
JP2002504916A (ja) 1997-06-21 2002-02-12 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗転移及び抗腫瘍活性を有するバルビツール酸誘導体
US6265578B1 (en) 1999-02-12 2001-07-24 Hoffmann-La Roche Inc. Pyrimidine-2,4,6-triones
PA8498701A1 (es) 1999-08-12 2002-08-26 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
US6468686B1 (en) * 2000-01-24 2002-10-22 Graftech Inc. Fluid permeable flexible graphite fuel cell electrode with enhanced electrical and thermal conductivity
MXPA03003734A (es) 2000-10-26 2003-07-28 Pfizer Prod Inc Inhibifores de metaloproteinasa del tipo pirimidin-2, 4, 6-triona.
US6841671B2 (en) 2000-10-26 2005-01-11 Pfizer Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
CA2480092A1 (en) 2002-04-26 2003-11-06 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
JP2005527598A (ja) 2002-04-26 2005-09-15 ファイザー・プロダクツ・インク トリアリール−オキシ−アリール−スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤

Also Published As

Publication number Publication date
EP1507535A1 (en) 2005-02-23
DOP2003000632A (es) 2003-10-31
AU2003223012A1 (en) 2003-11-10
TW200406407A (en) 2004-05-01
US6919332B2 (en) 2005-07-19
US20030232849A1 (en) 2003-12-18
PA8572101A1 (es) 2003-12-10
WO2003090751A1 (en) 2003-11-06
AR039660A1 (es) 2005-03-02
BR0309556A (pt) 2005-02-09
CA2483500A1 (en) 2003-11-06
MXPA04010550A (es) 2005-01-25
UY27775A1 (es) 2003-11-28
JP2005529889A (ja) 2005-10-06
GT200300098A (es) 2004-05-18

Similar Documents

Publication Publication Date Title
PE20040465A1 (es) Heteroariloxi-ariloxi-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa
NO20053587L (no) 3-(3,5-diokso-4,5-dihydro-3H-(1,2,4)triazin-2-yl-)benzamidderivater som P2X7-inhibitorer for behandling av inflammatoriske sykdommer.
CY1114022T1 (el) Φαρμακα με δραση υποδοχεα ημ74α
DE602004023207D1 (de) Benzimidazol-derivate als mek-hemmer
AR058719A1 (es) Derivados de isoxazol-4-il-oxadiazol
NO20075384L (no) Tiadiazolsubstituerte kumarinderivater og deres anvendelse som leukotrienbiosynteseinhibitorer.
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
ATE357434T1 (de) Disubstituierte thiazolylcarboxanilide und ihre verwendung als mikrobizide
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20040940A1 (es) Derivados de 3-cicloalquil-indol como inhibidores de la polimerasa del virus de hepatitis c
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
AR030507A1 (es) Compuesto de pirazolopiridina y los usos farmaceuticos del mismo
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
PE20040687A1 (es) Quinolinas sustituidas como antagonistas del receptor ccr5
PE20030601A1 (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados
DE60232510D1 (de) 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer
CO5611139A2 (es) Pirimidinas aril sustituidas y el uso de las mismas
PE20080068A1 (es) Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
HUP0401886A2 (hu) Kemokin receptor aktivitás modulátorokként alkalmazható piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
PE20040864A1 (es) Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
BRPI0312882B8 (pt) derivados de pleuromutilina e composição farmacêutica
CY1109300T1 (el) Νεοι συντηγμενοι ετεροκυκλικοι δακτυλιοι και χρησεις αυτων
ATE406353T1 (de) Piperidin-derivaten und deren verwendung bei der behandlung von durch chemokinen oder h1 vermittelten krankheiten

Legal Events

Date Code Title Description
FA Abandonment or withdrawal